Figure 4.

Kaplan–Meier graphs depicting OS in months for (A–C) patients in which CRCLM were not treated with systemic therapy and (D–F) patients in whom CRCLM were treated with systemic therapy. OS was stratified by (A, D) EGFR expression, (B, E) PTGS2 expression and (C, F) combined EGFR and PTGS2 expression. (A, B, D, E) HRR compares patients with high and low expression and (C,F) HRR compares patients in whom both EGFR and PTGS2 were highly expressed with patients in whom neither or either EGFR or PTGS2 levels were elevated. Information of systemic therapy was unavailable for n=11 and n=12 patients of which tissue samples were evaluated for EGFR and PTGS2 expression, respectively.